847,468 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 847,468 shares of the biopharmaceutical company's stock, valued at approximately $6,212,000. Peregrine Capital Management LLC owned 0.53% of Ocular Therapeutix as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of OCUL. GF Fund Management CO. LTD. bought a new position in shares of Ocular Therapeutix during the fourth quarter worth about $28,000. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $43,000. AlphaQuest LLC acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $53,000. GAMMA Investing LLC grew its stake in shares of Ocular Therapeutix by 6,760.0% during the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 8,112 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 8,446 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Stock Down 1.1%

OCUL traded down $0.10 during trading on Thursday, reaching $9.36. 1,158,707 shares of the stock were exchanged, compared to its average volume of 1,411,178. The stock has a market cap of $1.49 billion, a P/E ratio of -8.14 and a beta of 1.43. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22. The stock's 50 day moving average price is $8.13 and its two-hundred day moving average price is $7.83. Ocular Therapeutix, Inc. has a twelve month low of $5.79 and a twelve month high of $11.78.

Analyst Ratings Changes

A number of brokerages have recently commented on OCUL. Needham & Company LLC cut their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Royal Bank Of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective for the company. Finally, William Blair assumed coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Ocular Therapeutix presently has a consensus rating of "Buy" and an average price target of $17.33.

Insider Buying and Selling

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of the firm's stock in a transaction on Thursday, May 8th. The shares were purchased at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the acquisition, the director directly owned 172,704 shares in the company, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the sale, the insider directly owned 3,499,099 shares of the company's stock, valued at $25,123,530.82. The trade was a 0.60% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,079 shares of company stock valued at $208,739. Insiders own 2.30% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.